Antisense oligonucleotide therapy for urologic tumors.
Modulation of gene expression using antisense oligonucleotides has advanced from the laboratory to the clinic. Numerous companies can, at least partially, attribute their success to the development of antisense techniques, and one antisense drug is currently on the market. Antisense compounds have been used in clinical trials that included patients with urologic tumors, mostly directed at proliferation- or apoptosis-related targets. Furthermore, therapeutic inhibition of many new identified genes is being investigated in preclinical tests. This review provides a contemporary overview of current preclinical and clinical antisense oligonucleotide concepts for the treatment of urologic tumors.
Kausch
Ingo
I
Department of Urology, Medical University of Lübeck, Ratzeburger Allee 160, Germany.
Böhle
Andreas
A
D000818:Animals; D015972:Gene Expression Regulation, Neoplastic; D016259:Genes, myc / Q000235:genetics; D011905:Genes, ras / Q000235:genetics; D006801:Humans; D019394:Ki-67 Antigen / Q000235:genetics; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D011494:Protein Kinases / Q000235:genetics; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics; D019908:Proto-Oncogene Proteins c-raf / Q000235:genetics; D016212:Transforming Growth Factor beta / Q000235:genetics; D014571:Urologic Neoplasms / Q000235:genetics / Q000628:therapy*
D019394:Ki-67 Antigen; D016376:Oligonucleotides, Antisense; D019253:Proto-Oncogene Proteins c-bcl-2; D016212:Transforming Growth Factor beta; D011494:Protein Kinases; D019908:Proto-Oncogene Proteins c-raf